Tissue Regenix Group PLC Interim data from clinical trial of dCELL® Dermis (8873N)
October 04 2012 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 8873N
Tissue Regenix Group PLC
04 October 2012
4 October 2012
Tissue Regenix dCELL(R) Dermis produces encouraging results from
interim clinical data
Significant reduction in surface area of chronic wounds seen
after just six-weeks as healing is accelerated
York, 4 October 2012 - Interim data from the clinical trial of
Tissue Regenix Group plc ('Tissue Regenix') dCELL(R) Dermis
(application of human skin which has been treated with Tissue
Regenix' dCELL(R) process) has delivered very encouraging results.
The trial, which is being conducted at University Hospital South
Manchester, and involves 20 patients, has shown that treatment of
chronic wounds with Tissue Regenix dCELL(R) Dermis has led to a
significant reduction in the size of all wounds, while 45% of
patients have been completely healed.
The trial, which is being conducted in partnership with NHS
Blood and Transplant ('NHSBT'), and is due to complete by the end
of the year, is studying the effectiveness of dCELL(R) Dermis in
treating chronic wounds, consisting primarily of venous leg ulcers
that have failed to respond to standard treatments. Patients
involved in the trial had, on average, suffered with chronic ulcers
for more than four and a half years.
The key findings from the interim study are:
-- All but two patients have had a single application of dCELL dermis
-- All ulcers reduced in surface area (by an average of 50%) at the six-week point
-- Likewise, volume reduced significantly at the six-week point
-- Nine patients have been completely healed (study still ongoing)
The study is also highlighting another important advantage of
the dCELL(R) Dermis in that it is very easy to apply and can be
done without hospital admission - in either out-patient clinics and
potentially GP surgeries. The product also has a number of other
advantages in requiring no re-hydration and typically takes 30-40
minutes to apply and has been able to be tailored to fit all wounds
included in the study.
The Principle Investigator involved in the trial, Dr Ardeshir
Bayat of the University Hospital of South Manchester NHS Foundation
Trust said: "These are encouraging interim results. The
decellularised matrix appears to be providing a 'kick start' to
heal these difficult wounds. Chronic wounds of the lower leg are a
clinical challenge and their on-going treatment costs the NHS in
excess of GBP400m per annum. Therefore a novel solution that can
both reduce these costs and simultaneously offer a more effective
treatment strategy has been long overdue."
Antony Odell, Managing Director of Tissue Regenix commented:
"People who suffer with chronic leg ulcers often do so for many
years. Traditional treatments using compression bandages are not
effective in many cases and require regular hospital visits and the
associated disruption to their daily lives.
"However, early results from this trial indicate that our
dCELL(R) technology could play an important role in treating
patients who endure this painful condition, as well as deliver cost
effective solution to the NHS by negating the need for regular
treatment over a prolonged period."
-ENDS-
For Further Information
Tissue Regenix Group plc: 01904 435 176
Antony Odell
Ian Jefferson
Peel Hunt LLP (Nominated Adviser) 020 7418 8900
James Steel
Vijay Barathan
Newgate Communications
Alistair Kellie 07557 651840
Andrew Adie 07970 256512
Martin Greig 07584 221513
About Tissue Regenix
Tissue Regenix, (AIM:TRX) the regenerative medical devices
company , was incorporated in May 2006 to commercialise the
academic research of Professor Eileen Ingham and Professor John
Fisher from the University of Leeds in the field of tissue
decellularisation.
Notes
The pilot trial is treating patients who have failed to respond
to conventional treatments and is used in conjunction with a
portable compression therapy system
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAPEDEFDAFFF
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024